View in EDS HTML Full Text PDF Full Text

Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.

Saved in:
Bibliographic Details
Title: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
Authors: Dunn K; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA., Bushen J; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA., Luo D; Janssen Research & Development, LLC, Titusville, New Jersey, USA., Cai J; Janssen Research & Development, LLC, Spring House, Pennsylvania, USA., Simonson RB; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA., Anderson D; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
Source: HIV medicine [HIV Med] 2023 Mar; Vol. 24 (3), pp. 279-289. Date of Electronic Publication: 2022 Aug 15.
Publication Type: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
Journal Info: Publisher: Wiley Country of Publication: England NLM ID: 100897392 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1468-1293 (Electronic) Linking ISSN: 14642662 NLM ISO Abbreviation: HIV Med Subsets: MEDLINE
Database: MEDLINE Ultimate
Full text is not displayed to guests.
FullText Links:
  – Type: pdflink
Text:
  Availability: 1
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 36912173
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Dunn+K%22">Dunn K</searchLink>; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Bushen+J%22">Bushen J</searchLink>; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Luo+D%22">Luo D</searchLink>; Janssen Research & Development, LLC, Titusville, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Cai+J%22">Cai J</searchLink>; Janssen Research & Development, LLC, Spring House, Pennsylvania, USA.<br /><searchLink fieldCode="AU" term="%22Simonson+RB%22">Simonson RB</searchLink>; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.<br /><searchLink fieldCode="AU" term="%22Anderson+D%22">Anderson D</searchLink>; Janssen Scientific Affairs, LLC, Titusville, New Jersey, USA.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%22100897392%22">HIV medicine</searchLink> [HIV Med] 2023 Mar; Vol. 24 (3), pp. 279-289. <i>Date of Electronic Publication: </i>2022 Aug 15.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Wiley%22">Wiley </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>100897392 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1468-1293 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214642662%22">14642662 </searchLink><i>NLM ISO Abbreviation: </i>HIV Med <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36912173
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1111/hiv.13377
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 279
    Titles:
      – TitleFull: Darunavir/cobicistat/emtricitabine/tenofovir alafenamide in treatment-naïve (AMBER) and virologically suppressed (EMERALD) participants with neurological and/or psychiatric comorbidities: Week 96 subgroup analysis.
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Dunn K
      – PersonEntity:
          Name:
            NameFull: Bushen J
      – PersonEntity:
          Name:
            NameFull: Luo D
      – PersonEntity:
          Name:
            NameFull: Cai J
      – PersonEntity:
          Name:
            NameFull: Simonson RB
      – PersonEntity:
          Name:
            NameFull: Anderson D
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 03
              Text: 2023 Mar
              Type: published
              Y: 2023
          Identifiers:
            – Type: issn-electronic
              Value: 1468-1293
          Numbering:
            – Type: volume
              Value: 24
            – Type: issue
              Value: 3
          Titles:
            – TitleFull: HIV medicine
              Type: main
ResultId 1